Prothena Corp Public Ltd Co has disclosed a significant stock transaction involving William P. Scully, a ten percent owner of the company. The filing, made on October 6, 2026, reveals that Scully acquired 100,000 shares on October 2, 2026, at an average price of $8.57 per share. This acquisition indicates a strong commitment to the company and may reflect confidence in its future growth potential.
Prothena Corp, classified under SIC 2834 for Pharmaceutical Preparations, operates on the Nasdaq under the ticker symbol PRTA. The company has been active in the life sciences sector, focusing on developing treatments for various diseases. Recent filings show a pattern of stock transactions, highlighting ongoing investment activity by significant stakeholders.
The filing states, "These shares were purchased in multiple transactions at prices ranging from $8.5150 to $8.6098, inclusive." Following this transaction, Scully now holds a total of 314,000 shares directly. Additionally, he has indirect ownership of 187,000 shares through Manatee Equity Fund LLC.
This transaction may have implications for other stakeholders in Prothena, including investors and analysts observing the company's market movements. The pharmaceutical preparations industry is known for its volatility and potential for significant returns, making such insider transactions noteworthy.
Details were not available in the SEC filing regarding any future actions or plans following this transaction.